Definium Therapeutics, Inc.: Business Overview, Financials & Competitive Analysis
Definium Therapeutics, Inc. scores 8/10 on the AskCyborg Cyborg Score (Strong). Late-stage psychiatric therapeutic candidate with Phase 3 validation, FDA breakthrough status, and runway to accelerate DT120 toward market entry in major neuropsychiatric indications. Definium demonstrates strong execution with positive Phase 3 trial data, FDA Breakthrough Therapy designation, substantial cash runway through 2028, and significant capital raise (June 2026) to.
What is Definium Therapeutics, Inc.'s industry? Definium Therapeutics, Inc. (definiumtx.com) operates in Neurology Drugs. AskCyborg classifies Definium Therapeutics, Inc. under Neurology Drugs in its company registry.
Definium Therapeutics is a late-stage clinical biopharmaceutical company developing therapeutics intended to address underlying causes of psychiatric and neurological disorders. The company rebranded in January 2026 f...
Cyborg Score thesis
Late-stage psychiatric therapeutic candidate with Phase 3 validation, FDA breakthrough status, and runway to accelerate DT120...
Read the full analyst-debate transcript →Get the Latest Definium Therapeutics, Inc. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeDefinium Therapeutics, Inc. Overview
Pro stress-test →Definium Therapeutics is a late-stage clinical biopharmaceutical company developing therapeutics intended to address underlying causes of psychiatric and neurological disorders. The company rebranded in January 2026 from its former identity MindMed, reflecting its focus on a late-stage psychiatry pipeline anchored by DT120 ODT, a lysergide tartrate compound with FDA Breakthrough Therapy Designation for generalized anxiety disorder.
Strategic Profile
Pro stress-test →Definium is preparing for landmark FDA submissions in 2027 after completing three successful Phase 3 trials in anxiety and depression. As of 2025 full-year results, the company reported $411.6 million in cash, cash equivalents, and investments sufficient to fund operations into 2028.
Competitive Landscape
Pro stress-test →Definium competes in the emerging psychedelic medicine space against specialized psychiatric biotech companies. Primary competitors include Compass Pathways (NASDAQ: CMPS), developing psilocybin therapies for treatment-resistant depression; Atai Life Sciences/AtaiBeckley (NASDAQ: ATAI), with a diversified psychiatric pipeline; and GH Research (NASDAQ: GHRS), focused on ketamine-derived therapies. Definium's differentiation rests on Phase 3 validation for DT120 in anxiety and depression, FDA Breakthrough Therapy designation, and capital strength to execute late-stage development.
Industry Context
Definium Therapeutics, Inc. operates in Neurology Drugs.
Key facts
Founded: 2010 · Headquarters: New York, United States · Employees: 105 · Revenue: Private biopharmaceutical company—no product revenue; pre-commercial stage. Operating expenses dominate financials. · Market cap: $5.03 billion (as of October 9, 2026)